文献速递免疫规划卫生政策与健康促进

2019-2020年美国COVID-19疫苗安全监测中特别关注不良事件的背景发生率

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
PubMed 文献 · Vaccine · 2022-11-08

美国FDA BEST计划利用六个行政索赔数据库估计17种特别关注不良事件(AESI)的历史发生率,以作为COVID-19疫苗接种后安全监测的比较基准。研究纳入每年超过1亿参保人,发现AESI背景率因数据库和人口学特征而异,2020年3-12月间有所波动,但多数在2020年5月后恢复至大流行前水平。

要点

  • 2019年多数AESI发生率随年龄增长而升高。
  • 2020年3-5月多数AESI发生率低于2019年同期,5月后多数恢复至大流行前水平。
  • 比较历史率与接种后AESI率时需标准化人口学特征并考虑季节趋势。

核心结论

  • AESI背景率因数据库和人口学特征而异,并在2020年3-12月间波动,但多数在2020年5月后恢复至大流行前水平。
  • 在比较历史率与接种后AESI率时,标准化人口学特征并考虑季节和其他趋势至关重要。

研究设计与样本

  • 研究利用六个行政索赔数据库估计17种AESI的发生率,数据覆盖2019年1月1日至2020年12月11日。
  • Medicare索赔用于65岁及以上成人,商业索赔数据库(Blue Health Intelligence®、CVS Health、HealthCore Integrated Research Database、IBM® MarketScan® Commercial Database、Optum预 adjudicated claims)用于65岁以下成人。
  • 发生率按性别、年龄、种族/族裔(Medicare)和养老院居住状态(Medicare)在2019年及2020年特定时段进行估计。

主要发现

  • 研究每年纳入超过1亿参保人。
  • 2019年,多数AESI发生率随年龄增长而升高。
  • 与商业保险成人相比,Medicare参保者的过敏反应发生率较低(11 vs 12-19/10万人年),阑尾炎发生率较低(80 vs 117-155),发作性睡病发生率较低(38 vs 41-53)。
  • 在多数数据库和多数AESI中,男性发生率高于女性,且发生率因种族/族裔和养老院居住状态(Medicare)而异。
  • 急性心肌梗死(Medicare)和过敏反应(所有数据库)的发生率随季节变化;多数AESI在2020年3-5月低于2019年3-5月,但2020年5月后多数恢复至大流行前水平;贝尔麻痹、吉兰-巴雷综合征、发作性睡病和出血性/非出血性卒中在多个数据库中2020年5月后仍较低,而某些AESI(如弥散性血管内凝血)在2020年5月后高于2019年。

关键数值与推荐

  • 2019年Medicare参保者过敏反应发生率为11/10万人年,商业保险成人为12-19/10万人年。
  • 2019年Medicare参保者阑尾炎发生率为80/10万人年,商业保险成人为117-155/10万人年。
  • 2019年Medicare参保者发作性睡病发生率为38/10万人年,商业保险成人为41-53/10万人年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The U.S. Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative conducts active surveillance of adverse events of special interest (AESI) after COVID-19 vaccination. Historical incidence rates (IRs) of AESI are comparators to evaluate safety. METHODS: We estimated IRs of 17 AESI in six administrative claims databases from January 1, 2019, to December 11, 2020: Medicare claims for adults ≥ 65 years and commercial claims (Blue Health Intelligence®, CVS Health, HealthCore Integrated Research Database, IBM® MarketScan® Commercial Database, Optum pre-adjudicated claims) for adults < 65 years. IRs were estimated by sex, age, race/ethnicity (Medicare), and nursing home residency (Medicare) in 2019 and for specific periods in 2020. RESULTS: The study included >100 million enrollees annually. In 2019, rates of most AESI increased with age. However, compared with commercially insured adults, Medicare enrollees had lower IRs of anaphylaxis (11 vs 12-19 per 100,000 person-years), appendicitis (80 vs 117-155), and narcolepsy (38 vs 41-53). Rates were higher in males than females for most AESI across databases and varied by race/ethnicity and nursing home status (Medicare). Acute myocardial infarction (Medicare) and anaphylaxis (all databases) IRs varied by season. IRs of most AESI were lower during March-May 2020 compared with March-May 2019 but returned to pre-pandemic levels after May 2020. However, rates of Bell's palsy, Guillain-Barré syndrome, narcolepsy, and hemorrhagic/non-hemorrhagic stroke remained lower in multiple databases after May 2020, whereas some AESI (e.g., disseminated intravascular coagulation) exhibited higher rates after May 2020 compared with 2019. CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Moll K, Lufkin B, Fingar KR, et al. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020. Vaccine. 2022. PMID: 36404170. doi:10.1016/j.vaccine.2022.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。